BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35188810)

  • 1. Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis.
    Baek MH; Park EY; Ha HI; Park SY; Lim MC; Fotopoulou C; Bristow RE
    J Clin Oncol; 2022 May; 40(15):1659-1670. PubMed ID: 35188810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The survival outcome and complication of secondary cytoreductive surgery plus chemotherapy in recurrent ovarian cancer: a systematic review and meta-analysis.
    Ding T; Tang D; Xi M
    J Ovarian Res; 2021 Jul; 14(1):93. PubMed ID: 34256813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
    Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
    Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimally invasive interval cytoreductive surgery in ovarian cancer: systematic review and meta-analysis.
    Cardenas-Goicoechea J; Wang Y; McGorray S; Saleem MD; Carbajal Mamani SL; Pomputius AF; Markham MJ; Castagno JC
    J Robot Surg; 2019 Feb; 13(1):23-33. PubMed ID: 29992404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Meta analysis of whether cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy can improve survival in patients with colorectal cancer peritoneal metastasis].
    Liu D; Wang H; Yuan ZX; Chen WW; Wu ZJ; Liu XX; Luo J; Chu LL; Li Y; Cai J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):256-263. PubMed ID: 34645170
    [No Abstract]   [Full Text] [Related]  

  • 6. Secondary cytoreduction in platinum sensitive relapsed ovarian cancer: an individual patient level meta-analysis.
    Gulia S; Kannan S; Ghosh J; Rath S; Maheshwari A; Gupta S
    Int J Gynecol Cancer; 2023 Sep; 33(9):1440-1447. PubMed ID: 37567595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis.
    Goldberg RM; Kim SR; Fazelzad R; Li X; Brown TJ; May T
    Gynecol Oncol; 2022 Jan; 164(1):212-220. PubMed ID: 34756470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
    Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
    Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
    Costales AB; Chambers L; Chichura A; Rose PG; Mahdi H; Michener CM; Yao M; Debernardo R
    J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101844. PubMed ID: 32590110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: Systematic review and meta-analysis.
    Guida F; Dioun S; Fagotti A; Melamed A; Grossi A; Scambia G; Wright JD; Tergas AI
    Gynecol Oncol; 2022 Jul; 166(1):181-187. PubMed ID: 35550711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study.
    van de Laar R; Zusterzeel PL; Van Gorp T; Buist MR; van Driel WJ; Gaarenstroom KN; Arts HJ; van Huisseling JC; Hermans RH; Pijnenborg JM; Schutter EM; Pelikan HM; Vollebergh JH; Engelen MJ; Inthout J; Kruitwagen RF; Massuger LF
    BMC Cancer; 2014 Jan; 14():22. PubMed ID: 24422892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study.
    Falcone F; Scambia G; Benedetti Panici P; Signorelli M; Cormio G; Giorda G; Bogliolo S; Marinaccio M; Ghezzi F; Rabaiotti E; Breda E; Casella G; Fanfani F; Di Donato V; Leone Roberti Maggiore U; Greggi S
    Gynecol Oncol; 2017 Oct; 147(1):66-72. PubMed ID: 28716306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary cytoreductive surgery in recurrent epithelial ovarian cancer: A prognostic analysis with 103 cases.
    Fan XM; Zhang J; Niu SH; Li KX; Song CZ
    Int J Surg; 2017 Feb; 38():61-66. PubMed ID: 28027999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic Resection as Part of Cytoreductive Surgery in Advanced-stage and Recurrent Epithelial Ovarian Cancer--A Single-center Experience.
    Bacalbasa N; Balescu I; Dima S; Brasoveanu V; Popescu I
    Anticancer Res; 2015 Jul; 35(7):4125-9. PubMed ID: 26124365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?
    Kumar S; Srinivasan A; Phillips A; Madhupriya R; Pascoe J; Nevin J; Elattar A; Balega J; Cummins C; Sundar S; Kehoe ST; Singh K
    J Obstet Gynaecol; 2020 Aug; 40(6):849-855. PubMed ID: 31933417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When should Surgery be used for Recurrent Ovarian Carcinoma?
    Bommert M; Harter P; Heitz F; du Bois A
    Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):493-497. PubMed ID: 29743148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
    Coleridge SL; Bryant A; Kehoe S; Morrison J
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis.
    Bouchard-Fortier G; Cusimano MC; Fazelzad R; Sajewycz K; Lu L; Espin-Garcia O; May T; Bouchard-Fortier A; Ferguson SE
    Gynecol Oncol; 2020 Jul; 158(1):218-228. PubMed ID: 32387131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).
    Reuss A; du Bois A; Harter P; Fotopoulou C; Sehouli J; Aletti G; Guyon F; Greggi S; Mosgaard BJ; Reinthaller A; Hilpert F; Schade-Brittinger C; Chi DS; Mahner S
    Int J Gynecol Cancer; 2019 Oct; 29(8):1327-1331. PubMed ID: 31420412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
    Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
    Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.